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Abstract: Background: This analysis aimed to identify an operational, clinically relevant definition of response achieved 
in short-term clinical trials to support the identification of patients with Alzheimer’s disease (AD) who would benefit most 
from long-term galantamine therapy. Methods: Data were analyzed from 6 randomized placebo-controlled trials of up to 6 
months’ duration, which included patients with mild to moderate AD receiving maintenance doses of galantamine 16-24 
mg/day, and from 12 open-label extensions (galantamine 24 mg/day maintenance therapy). Assessments included changes 
from baseline in the 11-item AD Assessment Scale-Cognitive subscale (ADAS-Cog 11). Results: Pooled analysis of the 5-
6 month trial data showed that at the trial endpoint (2-5 months after reaching maintenance doses), the proportions of gal-
antamine- (n=1,173) versus placebo-treated patients (n=801) with probable AD categorized according to “improved”, 
“stable” or “non-rapid decline” criteria, were 45.8% versus 27.2%, 59.5% versus 37.1%, and 87.6% versus 69.7%, respec-
tively (observed cases analysis), whilst changes in ADAS-Cog 11 scores versus baseline were -4.9, -4.7 and -2.9 points, 
respectively, for “improved”, “stable” and “non-rapid decline” galantamine-treated patients (-1.5 points for galantamine 
recipients overall). “Improved” or “stable” galantamine-treated patients displayed mean improvement in ADAS-Cog 11 
scores over baseline until 18 months after starting treatment, and attenuated deterioration thereafter; for galantamine-
treated patients exhibiting “non-rapid decline”, mean ADAS-Cog 11 score returned to baseline after approximately 12 
months. Conclusions: Patients who demonstrate improvement, stability, or limited cognitive decline 2-5 months after 
reaching maintenance doses of galantamine are more likely to experience continued benefit from long-term galantamine 
therapy.
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INTRODUCTION 
  Galantamine is licensed for the treatment of mild to mod-
erate Alzheimer’s disease (AD) and is administered at main-
tenance doses of 16 or 24 mg daily [1]. The short-term cog-
nitive, functional and behavioral benefits of galantamine in 
patients with AD were established in double-blind, placebo-
controlled randomized clinical trials (RCTs) of 3-6 months’ 
duration [2-7]. Similar short-term beneficial effects were 
reported for patients with AD and cerebrovascular disease 
(AD+CVD) [8]. In long-term, open-label extensions (up to 
36 months), the cognitive decline observed in galantamine-
treated patients with AD appeared attenuated versus epide-
miologically based predictions of untreated decline [4, 9-11]. 
Furthermore, it has been estimated that each additional year 
of galantamine treatment is associated with a 27% reduction 
in the relative risk of permanent admission to a residential or 
nursing home [12]. 
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  The present analysis aimed to identify an operational, 
clinically relevant definition of response achieved in short-
term clinical trials that could aid clinicians in identifying 
patients with AD who would benefit most from long-term 
galantamine therapy. 
MATERIALS AND METHODS 
Data Sources 
  Analyses included data from 6 double-blind, placebo-
controlled RCTs in patients with mild to moderate AD 
(AD+CVD in GAL-INT-6), in which currently recom-
mended maintenance doses of galantamine (16-24 mg/day) 
were administered [3-8] (Fig. 1). All studies were carried out 
according to the Declaration of Helsinki and subsequent re-
visions, and were approved by institutional review boards or 
ethics committees. 
  All 6 studies enrolled patients with a history of cognitive 
decline; all except 1 study (GAL-INT-6) required that this be 
gradual in onset and progressive for at least 6 months. In all 
studies (except GAL-INT-6), patients met National Institute 
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Fig. (1). Overview of the 6 randomized, double-blind, placebo-controlled trials of galantamine (GAL) in patients with Alzheimer’s disease
(shaded boxes) and the subsequent open-label extensions included in the analyses. IR, immediate-release formulation (twice daily); n, number 
of patients starting the trial; PL, placebo; PR, prolonged-release formulation (once daily).  Note that 18 patients from GAL-USA-10 entered 
GAL-USA-12 without first completing GAL-USA-11. Also, 285 patients in GAL-INT-6 had Alzheimer’s disease with concomitant cere-
brovascular disease and were included in the analyses; the remaining 307 patients in this trial had probable vascular dementia and were ex-
cluded from the analyses. 
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and the Alzheimer’s Disease and Related Disorders Associa-
tion (NINCDS-ADRDA) [13] criteria for probable AD. Pa-
tients in study GAL-INT-6 met either NINCDS-ADRDA 
criteria for possible AD or National Institute of Neurological 
Disorders and Stroke and Association Internationale pour la 
Recherche et l’Enseignement en Neurosciences (NINDS-
AIREN) International Workshop [14] criteria for probable 
vascular dementia (VAD). For all studies, eligible patients 
were required to have baseline Mini-Mental State Examina-
tion (MMSE) [15] scores of 10–25. Baseline scores on the 
11-item Cognitive subscale of the Alzheimer’s Disease As-
sessment Scale (ADAS-Cog) [16] had to be  12 in all except 
two studies where it had to be  18. The reported mean ages 
for all study groups ranged from 72-78 years. 
  In one study (GAL-INT-10), both immediate- and pro-
longed-release galantamine arms were included in the analy-
sis. In a flexible-dose trial (GAL-INT-2), which used a gal-
antamine arm of 24 or 32 mg daily, all galantamine-treated 
patients were included. 
  Only the subgroup of patients (~50%) with AD+CVD 
were included from the GAL-INT-6 study, providing data for 
an AD population with a comorbidity commonly observed in 
clinical practice. Patients with VAD were excluded. 
  Data from patients who received galantamine 8 mg/day 
(GAL-USA-10 [n=140]) or 32 mg/day (GAL-INT-1 [n=218] 
or GAL-USA-1 [n=211]) maintenance doses, and who could 
progress to the open-label phase, were excluded from the 
responder analyses described in this paper. 
  Data from 12 long-term, open-label extensions of the 
RCTs, some of which have been published [4, 9-11] were 
included (Fig. 1) to determine whether the initial response to 
galantamine was predictive for long-term response. All long-
term extension trials used galantamine 24 mg/day as the 
maintenance dosage, with systematic follow-up using stan-
dardized scheduled assessments of tolerability and efficacy. 
Responder Definitions 
  ADAS-Cog 11 was used to measure cognitive response. 
A negative change on this scale indicates improvement in 
cognition, whereas a positive change indicates deterioration. 
For our analyses, the following (non-mutually exclusive) 
definitions were used: 
Responder 1 — Improved 
  Stable or improved cognition (ADAS-Cog 11 score 
change from baseline 0) AND improved global assessment 
(Clinician’s Interview-Based Impression of Change with 
Caregiver Input [CIBIC-plus] or Clinician’s Global Impres-
sion of Change [CGIC]); OR function (AD Cooperative 
Study of Activities of Daily Living Inventory [ADCS-ADL] 
or Disability Assessment for Dementia [DAD]); OR behav-
ior (Neuropsychiatric Inventory [NPI]). 
Responder 2 — Stable 
  Stable or improved cognition (ADAS-Cog 11 score 
change from baseline 0) AND stable or improved global 
assessment (CIBIC-plus or CGIC), OR function (ADCS-
ADL or DAD), OR behavior (NPI). 
Responder 3 — Non-Rapid Decline 
  Improvement, stability, or minimal deterioration in cog-
nition (ADAS-Cog 11 score change from baseline  4
points). This group of patients therefore excludes only those 
whose cognition declines rapidly. 
  Each trial used 1 global (CIBIC-plus or CGIC) and 1 
functional (ADCS-ADL or DAD) assessment. In some trials 
where NPI data were not collected, analyses were limited to 
cognition, function and global scores in terms of estimating 
improvement and/or stabilization. 
Analyses 
  To assess the short-term efficacy of galantamine, data 
from the 4 RCTs (GAL-INT-1, GAL-INT-10, GAL-USA-1 
and GAL-USA-10) in patients with probable AD considered 
to be of adequate duration to ascertain effectiveness (assess-
ments 2-5 months after attainment of maintenance dose) 
were pooled using simple pooled analysis with no covariates. 
Data are also presented separately for these trials, as well as 
for the subgroup of patients with possible AD+CVD from 
GAL-INT-6.
  Three sets of analyses were performed, enabling evalua-
tion not only of patients who completed the trials, but also 
including individuals who withdrew from the studies. The 
observed-cases (OC) analysis was based on changes in 
scores (from baseline) for patients who completed the trials 
and for whom the relevant instruments were sufficiently 
complete to allow calculation of change scores. The last ob-
servation carried forward (LOCF) analysis included patients 
who completed at least 1 post-baseline assessment (i.e., the 
intent-to-treat population), and, for those who withdrew, the 
measurement from the last (post-baseline) assessment avail-
able was carried forward to allow calculation of score 
changes. The observed cases plus (OC+) analysis was based 
on observed cases plus an LOCF determination for a small 
number of patients who discontinued due to lack of efficacy. 
Particular attention was given to identifying patients who 
discontinued due to lack of efficacy. In the first instance, 
category responses recorded on the study termination form 
for “inefficacy” and “insufficient response” (n=18) were 
utilized. To ensure completeness, an additional search was 
conducted of individual verbatim comments on the trial ter-
mination form for other general categories such as “subject 
withdrew consent” and “other”, that led to the identification 
of a further 14 cases (32 in total, <1%) in which inefficacy or 
similar wording was mentioned. In common with LOCF 
analyses, such patients were included if they had at least 1 
post-baseline assessment (n=20). 
  To evaluate long-term efficacy, ADAS-Cog 11 changes 
for patients with probable AD who originally participated in 
the 5-6 month trials and the subsequent open-label exten-
sions (Fig. 1) were assessed for up to 48 months post-
treatment initiation in both short-term responders and non-
responders. Analyses were repeated including AD+CVD 
patients. These data were compared with the predicted 
change in cognition for untreated patients using the Stern 
equation estimates of ADAS-Cog 11 decline [17]. The Stern 
prediction of decline was used as a benchmark for the ex-
pected long-term untreated deterioration in cognition, as 178    Current Alzheimer Research, 2011, Vol. 8, No. 2  Kavanagh et al. 
measured by the ADAS-Cog 11 score in the absence of 
treatment. The Stern model takes into account the baseline 
ADAS-Cog 11 score and uses the time from that score to 
predict the longitudinal rate of decline [17]. A quadratic rela-
tionship has been demonstrated between the severity of AD 
and the rate of cognitive decline, with good agreement be-
tween observed and predicted changes [12]. To account for 
potential dropout bias, an additional corrected Stern estimate 
based on the baseline characteristics of patients available at 
each assessment point was also used. 
RESULTS 
  A total of 3,523 patients participated in the 5 RCTs of 5-
6 months’ duration; this included 285 patients with 
AD+CVD in GAL-INT-6, but excluded 307 patients in the 
same trial with VAD. Reasons for discontinuation from these 
trials included adverse events (11%), withdrawal of consent 
(3%), noncompliance (2%), loss to follow-up (<1%), insuffi-
cient response/inefficacy (<1%), ineligible to continue 
(<1%), death (<1%), and other (4%). 
  Following the RCTs, a total of 2,266 patients subse-
quently entered the open-label extension trials. Reasons for 
discontinuation during the open-label extensions included 
adverse events (21%), withdrawal of consent (7%), death 
(4%), insufficient response/inefficacy (3%), noncompliance 
(2%), loss to follow-up (1%), did not enter Year 2 (1%), in-
eligible to continue (<1%), and other (8%). After completing 
one open-label trial, 5% of patients did not enter a further 
open-label study for which they were subsequently eligible. 
The reasons for eligible patients not proceeding from one 
open-label study to the next were not available. 
Short-Term Treatment Response 
  Analysis of the total pooled probable AD (i.e., excluding 
AD+CVD) 5- to 6-month trial population (OC analyses) 
showed that galantamine-treated patients improved by 1.5 
points (vs. baseline) on the ADAS-Cog 11 scale, whereas the 
placebo group deteriorated by 1.8 points (overall galan-
tamine treatment benefit, 3.3 points; p<0.001) (Table 1). (In 
patients with possible AD+CVD, overall treatment benefit 
was 2.8 points on the ADAS-Cog 11 scale [p<0.001].)
Proportion of Responders: “Responder 1 — Improved” 
Definition 
  Among patients with probable AD, 45.8% of galan-
tamine-treated patients met the “Responder 1 — improved” 
criteria compared with 27.2% of placebo recipients. (In pa-
tients with possible AD+CVD, 47.4% and 35.6% of the gal-
antamine and placebo groups, respectively, met the “Re-
sponder 1 — improved” criteria). 
  The magnitude of improvement on the ADAS-Cog 11 
scale was greater for patients meeting the “Responder 1 — 
improved” criteria (4.9 points) compared with the overall 
galantamine group (1.5 points) (Table 1). 
  The other analyses (OC+ and LOCF) showed broadly 
consistent findings (Table 1). Because relatively few patients 
discontinued due to lack of efficacy, results for the OC and 
OC+ analyses were almost identical in terms of the propor-
tions of patients meeting the “Responder 1 — improved” 
criteria as well as in the magnitude of changes in ADAS-Cog 
11 scores from baseline.
  “Responder 1” rates were higher in trials in which behav-
ior was measured (Fig. 2). In the LOCF analysis, the propor-
tions of galantamine-treated patients fulfilling the criteria for 
“Responder 1 — improved” ranged from 44.8% to 49.1% 
compared with 30.2% to 32.4% in trials without a behavioral 
measure. Similar differences in “Responder 1” rates for gal-
antamine-treated patients in trials with or without a behav-
ioral measure were noted for the OC and OC+ analyses (data 
not shown). 
Proportion of Responders: “Responder 2 — Stable” 
Definition 
  The proportion of probable AD patients meeting the “Re-
sponder 2 — stable” criteria was 59.5% with galantamine 
versus 37.1% with placebo (OC analysis) (Table 2). (In pa-
tients with possible AD+CVD, “Responder 2” rates were 
consistent, with 52.7% and 39.1% for the galantamine and 
placebo groups, respectively.) The proportions of patients 
meeting the “Responder 2 — stable” criteria in the OC+ and 
LOCF analyses were consistent with these findings (data not 
shown). Overall, when this “stable” definition of response 
was applied, the magnitude of treatment change in the 
ADAS-Cog 11 score at endpoint in both galantamine and 
placebo groups was similar to that when the “Responder 1 — 
improved” criteria were used (Table 1) e.g., -4.9 points on 
the ADAS-Cog 11 scale in the galantamine “Responder 1” 
group versus -4.7 points in the galantamine “Responder 2” 
group (Tables 1 and 2). 
Proportion of Responders: “Responder 3 —Non-Rapid 
Decline” Definition  
  The proportion of patients with probable AD who met the 
“Responder 3 — non-rapid decline” criteria was 87.6% with 
galantamine versus 69.7% with placebo (OC analysis) (Table 
2). (In patients with possible AD+CVD, “Responder 3” rates 
were 82.9% and 72.4% for galantamine and placebo, respec-
tively.) The proportions of patients meeting “Responder 3 — 
non-rapid decline” criteria in the OC+ and LOCF analyses 
were consistent with these findings (data not shown). Over-
all, when this “non-rapid decline” definition of response was 
used, the magnitude of change in the ADAS-Cog 11 score 
versus baseline at endpoint was -2.9 points, somewhat lower 
compared to “Responder 1” (-4.9 points) and “Responder 2” 
(-4.7 points), but still greater than for the treatment group as 
a whole (-1.5 points) (Tables 1 and 2).  
Long-Term Effects in Responders and Non-Responders 
  Galantamine-treated patients with probable AD who met 
the “Responder 1— improved” criteria displayed a mean 
improvement in ADAS-Cog 11 scores versus baseline until 
18 months after initiation of treatment, with an attenuated 
rate of deterioration thereafter (Fig. 3A). In galantamine-
treated patients who met the “Responder 1” non-response 
criteria, the deterioration in mean ADAS-Cog 11 scores was 
somewhat less than for the Stern prediction of untreated de-
cline (adjusted for the dropout of more advanced patients 
over time) (Fig. 3B). Treatment Response to Galantamine  Current Alzheimer Research, 2011, Vol. 8, No. 2    179
Table 1.  Effects of Galantamine on Cognition (ADAS-Cog 11 Scale) in Pooled AD Trials Using the “Responder 1 — Improved” 
Criteria (Stable or Improved Cognition, and Improved Global Assessment or Function or Behavior)
a for Responders at 
Endpoint (5-6 Months) 
No. of Patients   
(at Baseline) 
Mean Cognition 
Score (SD) at Base-
line [95% CI] 
No. (%) of Patients at
Endpoint 
Mean Cognition 
Score (SD) at End-
point [95% CI] 
Mean Change in 
Cognition Score (SD)
from Baseline to 
Endpoint
b [95% CI] 
OC Analysis 
Galantamine (16-24 mg) 
Total 1,173 
26.6 (9.8) 
[26.1, 27.2] 
1,173 
25.1 (10.9) 
[24.5, 25.7] 
-1.5 (5.9) 
[-1.8, -1.2] 
Responders NA 
27.2 (9.5) 
[26.4, 28.0] 
537 (45.8) 
22.3 (9.5) 
[21.5, 23.1] 
-4.9 (4.1) 
[-5.3, -4.6] 
Non-responders NA 
26.1 (10.0) 
[25.3, 26.9] 
636 (54.2) 
27.5 (11.4) 
[26.6, 28.4] 
1.4 (5.6) 
[0.9, 1.8] 
Placebo 
Total 801 
25.8 (9.7) 
[25.1, 26.5] 
801
27.6 (12.4) 
[26.8, 28.5] 
1.8 (6.1) 
[1.4, 2.3] 
Responders NA 
23.5 (8.5) 
[22.4, 24.7] 
218 (27.2) 
20.0 (8.5) 
[18.8, 21.1] 
-3.6 (3.0) 
[-4.0, -3.2] 
Non-responders NA 
26.6 (10.0) 
[25.8, 27.4] 
583 (72.8) 
30.5 (12.4) 
[29.5, 31.5] 
3.9 (5.7) 
[3.4, 4.3] 
OC+ Analysis 
Galantamine (16-24 mg) 
Total 1,183 
26.6 (9.8) 
[26.1, 27.2] 
1,183 
25.1 (10.8) 
[24.5, 25.7] 
-1.5 (5.9) 
[-1.8, -1.2] 
Responders NA 
27.2 (9.5) 
[26.4, 28.0] 
541 (45.7) 
22.3 (9.4) 
[21.5, 23.1] 
-4.9 (4.1) 
[-5.3, -4.6] 
Non-responders NA 
26.1 (10.0) 
[25.3, 26.9] 
642 (54.3) 
27.5 (11.4) 
[26.6, 28.4] 
1.4 (5.6) 
[1.0, 1.8] 
Placebo 
Total 811 
25.9 (9.8) 
[25.2, 26.5] 
811
27.7 (12.4) 
[26.9, 28.6] 
1.8 (6.1) 
[1.4, 2.3] 
Responders NA 
23.6 (8.5) 
[22.5, 24.7] 
220 (27.1) 
20.0 (8.5) 
[18.9, 21.2] 
-3.6 (3.0) 
[-4.0, -3.2] 
Non-responders NA 
26.7 (10.1) 
[25.9, 27.5] 
591 (72.9) 
30.6 (12.4) 
[29.6, 31.6] 
3.9 (5.7) 
[3.4, 4.3] 
LOCF Analysis 
Galantamine (16-24 mg) 
Total 1,466 
27.0 (9.9) 
[26.5, 27.5] 
1,466 
25.6 (10.9) 
[25.1, 26.2] 
-1.4 (5.7) 
[-1.6, -1.1] 
Responders NA 
27.3 (9.6) 
[26.6, 28.1] 
644 (43.9) 
22.6 (9.5) 
[21.8, 23.3] 
-4.7 (4.0) 
[-5.0, -4.4] 
Non-responders NA 
26.7 (10.2) 
[26.0, 27.4] 
822 (56.1) 
28.0 (11.4) 
[27.2, 28.8] 
1.3 (5.4) 
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(Table 1) contd….. 
No. of Patients   
(at Baseline) 
Mean Cognition 
Score (SD) at Base-
line [95% CI] 
No. (%) of Patients at
Endpoint 
Mean Cognition 
Score (SD) at End-
point [95% CI] 
Mean Change in 
Cognition Score (SD)
from Baseline to 
Endpoint
b [95% CI] 
Placebo 
Total 951 
26.4 (10.1) 
[25.8, 27.1] 
951
28.1 (12.5) 
[27.3, 28.9] 
1.7 (6.0) 
[1.3, 2.1] 
Responders NA 
24.3 (8.8) 
[23.2, 25.4] 
254 (26.7) 
20.6 (8.8) 
[19.5, 21.7] 
-3.7 (3.1) 
[-4.1, -3.3] 
Non-responders NA 
27.2 (10.5) 
[26.4, 28.0] 
697 (73.3) 
30.9 (12.5) 
[30.0, 31.8] 
3.7 (5.6) 
[3.3, 4.1] 
aAt 5 to 6 months: Change in ADAS-Cog 11 scores was 0 AND there was improved global (CIBIC-plus or CGIC) OR functional (ADCS-ADL or DAD) OR behavioral assessment 
(NPI). Each trial used 1 global assessment (either CIBIC-plus or CGIC) and 1 functional assessment (either ADCS-ADL or DAD). In a number of trials, NPI data were not collected. 
bA negative change in the score indicates improvement; a positive change indicates deterioration. AD, Alzheimer’s disease; ADAS-Cog 11, 11-item Alzheimer’s Disease Assessment 
Scale–Cognitive subscale; ADCS-ADL, AD Cooperative Study of Activities of Daily Living Inventory; CGIC, Clinician’s Global Impression of Change; CI, confidence interval; 
CIBIC-plus, Clinician’s Interview-Based Impression of Change with Caregiver Input; DAD, Disability Assessment for Dementia; LOCF, intent-to-treat analysis with missing data for 
patients who discontinued, computed as the last observation carried forward; NPI, Neuropsychiatric Inventory; OC, observed cases; OC+, OC analysis with LOCF for patients who 
discontinued due to lack of efficacy; SD, standard deviation; NA, not applicable. 
Table 2.  Effects of Galantamine on Cognition (ADAS-Cog 11 Scale) in AD Pooled Trials Using “Responder 2 — Stable” (Stable or 
Improved Cognition, and Stable or Improved Global Assessment or Function or Behavior)
a or “Responder 3 — Non-rapid 
Decline” (Improvement, Stability, or Minimal Deterioration in Cognition)
b Criteria for Responders at Endpoint (5-6 
Months) 
No. of Patients  
(at Baseline) 
Mean Cognition 
Score (SD) at Base-
line [95% CI] 
No. (%) of Patients at
Endpoint 
Mean Cognition 
Score (SD) at  
Endpoint  [95% CI] 
Mean Change in 
Cognition Score (SD)
from Baseline to 
Endpoint
c [95% CI] 
“Stable” Response Criteria
a (OC analysis) 
Galantamine (16-24 mg) 
Total 1,173 
26.6 (9.8) 
[26.1, 27.2] 
1,173 
25.1 (10.9) 
[24.5, 25.7] 
-1.5 (5.9) 
[-1.8, -1.2] 
Responders NA 
26.8 (9.5) 
[26.1, 27.5] 
698 (59.5) 
22.1 (9.3) 
[21.4, 22.8] 
-4.7 (4.0) 
[-5.0, -4.4] 
Non-responders NA 
26.4 (10.2) 
[25.5, 27.3] 
475 (40.5) 
29.6 (11.4) 
[28.6, 30.6] 
3.2 (5.0) 
[2.7, 3.6] 
Placebo 
Total 801 
25.8 (9.7) 
[25.1, 26.5] 
801
27.6 (12.4) 
[26.8, 28.5] 
1.8 (6.1) 
[1.4, 2.3] 
Responders NA 
23.3 (8.5) 
[22.3, 24.3] 
297 (37.1) 
19.8 (8.4) 
[18.9, 20.8] 
-3.4 (3.0) 
[-3.8, -3.1] 
Non-responders NA 
27.2 (10.1) 
[26.4, 28.1] 
504 (62.9) 
32.2 (12.0) 
[31.1, 33.2] 
5.0 (5.3) 
[4.5, 5.4] 
“Non-Rapid Decline” Response Criteria
b (OC Analysis)
Galantamine (16-24 mg) 
Total 1,173 
26.6 (9.8) 
[26.1, 27.2] 
1,173 
25.1 (10.9) 
[24.5, 25.7] 
-1.5 (5.9) 
[-1.8, -1.2] 
Responders NA 
26.5 (9.8) 
[25.9, 29.2] 
1,028 (87.6) 
23.6 (9.9) 
[23.0, 24.2] 
-2.9 (4.6) 
[-3.2, -2.6] Treatment Response to Galantamine  Current Alzheimer Research, 2011, Vol. 8, No. 2    181
(Table 2) contd…. 
No. of Patients  
(at Baseline) 
Mean Cognition 
Score (SD) at Base-
line [95% CI] 
No. (%) of Patients at
Endpoint 
Mean Cognition 
Score (SD) at  
Endpoint  [95% CI] 
Mean Change in 
Cognition Score (SD)
from Baseline to 
Endpoint
c [95% CI] 
Non-responders NA 
27.6 (9.9) 
[25.9, 29.2] 
145 (12.4) 
36.1 (11.2) 
[34.2, 37.9] 
8.5 (4.1) 
[7.8, 9.2] 
Placebo
Total 801
25.8 (9.7) 
[25.1, 26.5] 
801
27.6 (12.4) 
[26.8, 28.5] 
1.8 (6.1) 
[1.4, 2.3] 
Responders NA 
24.4 (9.1) 
[23.6, 25.1] 
558 (69.7) 
23.1 (9.8) 
[22.3, 23.9] 
-1.2 (3.8) 
[-1.6, -0.9] 
Non-responders NA 
29.0 (10.4) 
[27.7, 30.3] 
243 (30.3) 
37.9 (11.5) 
[36.5, 39.4] 
8.9 (4.3) 
[8.4, 9.5] 
aAt 5 to 6 months: Change in ADAS-Cog 11 scores was 0 AND there was stable/improved global (CIBIC-plus or CGIC) OR functional (ADCS-ADL or DAD) OR behavioral as-
sessment (NPI). Each trial used 1 global assessment (either CIBIC-plus or CGIC) and 1 functional assessment (either ADCS-ADL or DAD). In a number of trials, NPI data were not 
collected. 
bAt 5 to 6 months: Patient either improved, stable, or showed a deterioration of 4 points or fewer on the ADAS-Cog 11 scale. 
cA negative change in the score indicates 
improvement; a positive change indicates deterioration. AD, Alzheimer’s disease; ADAS-Cog 11, 11-item Alzheimer’s Disease Assessment Scale–Cognitive subscale; ADCS-ADL, 
AD Cooperative Study of Activities of Daily Living Inventory; CGIC, Clinician’s Global Impression of Change; CI, confidence interval; CIBIC-plus, Clinician’s Interview-Based 
Impression of Change with Caregiver Input; DAD, Disability Assessment for Dementia; NPI, Neuropsychiatric Inventory; OC, observed cases; SD, standard deviation; NA, not 
applicable. 
Fig. (2). Responder rates (“Responder 1 — improved” definition: stable/improved cognition, and improved global assessment or function or 
behavior) for galantamine- and placebo-treated patients in individual trials of 5-6 months’ duration (LOCF analysis). LOCF analysis is de-
fined as the intent-to-treat analysis with missing data for patients who discontinued, computed as the last observation carried forward. 
  Similarly, when the “Responder 2 — stable” group was 
considered, there was also a mean improvement in ADAS-
Cog 11 scores versus baseline for galantamine-treated pa-
tients until 18 months after initiation of treatment, with a 
similarly attenuated rate of deterioration thereafter (Fig. 4A). 
The observed deterioration in mean ADAS-Cog 11 scores 
among galantamine-treated patients who met the “Responder 
2” non-response criteria was closer to the Stern-predicted 
untreated deterioration (Fig. 4B), although some individual 
patients in this group outperformed their Stern-predicted 
untreated decline. 
  For galantamine-treated patients with probable AD who 
met the “Responder 3 — non-rapid decline” definition, ap-
proximately 12 months elapsed before the mean recorded 
ADAS-Cog 11 score returned to the baseline level. Beyond 
12 months, the observed deterioration was less than the 
Stern-predicted untreated decline (Fig. 5A). For galan-
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Fig. (3). Long-term changes in scores on the 11-item Alzheimer’s Disease Assessment Scale–Cognitive subscale (ADAS-Cog 11) for re-
sponders to galantamine (A), defined as “improved” (“Responder 1” criteria: stable/improved cognition, and improved global assessment or 
function or behavior) at 5-6 months, compared with the Stern prediction [17] of untreated decline (unadjusted and adjusted for the baseline 
characteristics of patients available at each assessment point). Non-responders are also shown (B). 
A. Responder (based on “Responder 1 — improved” criteria)
B. Non-responder (based on “Responder 1 — improved” criteria)Treatment Response to Galantamine  Current Alzheimer Research, 2011, Vol. 8, No. 2    183
Fig. (4). Long-term changes in scores on the 11-item Alzheimer’s Disease Assessment Scale–Cognitive subscale (ADAS-Cog 11) for re-
sponders to galantamine (A), defined as “stable” (“Responder 2” criteria: stable/improved cognition, and stable/improved global assessment 
or function or behavior) at 5-6 months, compared with the Stern prediction [17] of untreated decline (unadjusted and adjusted for the baseline 
characteristics of patients available at each assessment point). Non-responders are also shown (B). 
A. Responder (based on “Responder 2 — stable” criteria)
B. Non-responder (based on “Responder 2 — stable” criteria)184  Current Alzheimer Research, 2011, Vol. 8, No. 2  Kavanagh et al. 
Fig. (5). Long-term changes in scores on the 11-item Alzheimer’s Disease Assessment Scale–Cognitive subscale (ADAS-Cog 11) for re-
sponders to galantamine (A), defined as “non-rapid decline” (“Responder 3” criteria: improvement, stability, or minimal deterioration in cog-
nition) at 5-6 months, compared with the Stern prediction [17] of untreated decline (unadjusted and adjusted for the baseline characteristics of 
patients available at each assessment point). Non-responders are also shown (B). 
A. Responder (based on “Responder 3 — non-rapid decline” criteria)
B. Non-responder (based on “Responder 3 — non-rapid decline” criteria)Treatment Response to Galantamine  Current Alzheimer Research, 2011, Vol. 8, No. 2    185
tamine-treated patients who met the “Responder 3” non-
response criteria, the observed mean deterioration in ADAS-
Cog 11 scores was very similar to the Stern-predicted un-
treated decline (Fig. 5B), and relatively few individual pa-
tients who met the non-response criteria outperformed their 
Stern-predicted untreated decline. 
  Consistent results were obtained across all three re-
sponder definitions when analyses were conducted that also 
included patients with AD+CVD (data not shown). 
DISCUSSION 
  The results of the present pooled analyses suggest that 
patients who demonstrate improvement, stability on assess-
ments of cognition and other domains such as func-
tion/behavior, or non-rapid cognitive decline 5-6 months 
after the initiation of galantamine therapy are more likely to 
experience continued benefit from long-term therapy. Pa-
tients who exhibit rapid cognitive decline at 5-6 months 
(such as >4 points on the ADAS Cog-11 scale or >2 points 
on the MMSE) are likely to be non-responders to long-term 
galantamine therapy. It is thus possible that currently used 
definitions of response that require improvement may result 
in the exclusion of a substantial proportion of patients who 
could potentially benefit from longer-term treatment. The 
current analyses suggest that patients with “stable” and to a 
lesser extent “non-rapid decline” definitions of response may 
also benefit from galantamine therapy in the long term. 
However, when considering the data presented in this analy-
sis, it is important to take into account both the strengths and 
weaknesses of our study. 
  The retention of elderly and frail patients (and their care-
givers — who may also be elderly and infirm) in clinical 
trials is a major challenge. Nevertheless, retention rates in 
the present long-term trials were reasonably satisfactory and 
so data were available for >1,100 patients continuously 
treated with galantamine for 12 months, >500 treated for 24 
months, and >300 treated for 36 months. (As mentioned ear-
lier, patients who had previously received galantamine 8 
mg/day [in study GAL-USA-1032] or 32 mg/day [in studies 
GAL-INT-1 or GAL-USA-1] were excluded from the re-
sponder analyses). 
  The discontinuation rate in the first 6 months due to lack 
of efficacy was very low (<1%), even when trial databases 
were “hand-searched” for such patients. Therefore, inclusion 
of such patients likely had little impact on the analysis. In 
line with the double-blind trials, the data from the open-label 
extension studies — the original objectives of which were to 
examine the long-term safety of galantamine rather than 
long-term efficacy — showed that most patients who discon-
tinued did so as a consequence of adverse events; lack of 
efficacy was given as the reason for discontinuation from the 
open-label extension studies in only 3% of instances. Never-
theless, selection effects with trial withdrawals cannot be 
precluded. The substantial drop in patient numbers observed 
in the present analysis after 12 months should also be ac-
knowledged. To control for the possibility of selective drop-
outs, as previously mentioned, a corrected Stern estimate, 
based on the baseline characteristics of patients available at 
each assessment point, was used when evaluating the data. 
  The Stern equation was used in the absence of placebo 
data and we accept that the analysis of these trials was lim-
ited by the lack of a long-term placebo group. Recruitment 
and long-term retention of a meaningful placebo group was 
precluded for both ethical and practical reasons due to the 
availability of established licensed medications for AD. (In-
deed, the availability of licensed medications for AD has 
affected patient recruitment/retention in other studies [18] 
and may result in newly developed drugs with potential dis-
ease-modifying effects [19] being administered as adjuvant 
therapies.) Under these circumstances, long-term placebo 
groups might not have provided representative comparators. 
Whilst the Stern equation provides a useful benchmark based 
on epidemiological modeling of long-term deterioration in 
untreated patients, the limitations of such methodology 
should be noted — these limitations include deriving esti-
mates from data involving relatively small numbers of pa-
tients. Comparison of the Stern equation with 1-year placebo 
data from two clinical trials of patients with mild to moder-
ate AD showed a reasonably good level of agreement in the 
overall population [20]. However, the predicted decline in 
patients with moderate AD was less than observed in the trial 
data, suggesting that the Stern estimates may be conservative 
[20], and predictions in subgroups of patients should be in-
terpreted cautiously [21]. 
  We consider that the “Responder 2 — stable” criteria 
may be regarded as the best performing of the three “Re-
sponder” definitions we have described. External review of 
these data [21], which were originally submitted to the Na-
tional Institute for Health and Clinical Excellence (NICE) in 
England and Wales, suggested that the “Responder 2 — sta-
ble” criteria were not significantly affected by potential re-
gression to the mean and that the “Responder 2 — stable” 
criteria did not lead to significant diminution in treatment 
effect compared to “Responder 1 — improved” criteria. With 
the “Responder 3 — non-rapid decline” criteria, a higher 
proportion of placebo responders was apparent: the propor-
tions of placebo responders after 5-6 months according to 
“Responder 1 — improved”, “Responder 2 — stable” and 
“Responder 3 — non-rapid decline” criteria were 27.2, 37.1 
and 69.7%, respectively (OC analyses). Given the higher 
proportion of placebo responders with the “Responder 3” 
criteria, a greater degree of regression to the mean might 
have been expected in this instance. However, with the “Re-
sponder 3” criteria, the mean baseline ADAS-Cog 11 score 
was higher in placebo non-responders than in placebo re-
sponders (29.0 vs 24.4 points), and this should have resulted 
in a greater effect in placebo non-responders if regression to 
the mean was exerting a substantial effect. Furthermore, if 
the effects of regression to the mean had influenced the re-
sults, decline in non-responding patients may have been un-
derestimated, whilst for responders changes could have been 
evaluated conservatively. This would strengthen our argu-
ment relating to potential benefits of galantamine therapy. 
(For all definitions of response, mean cognition scores at 
baseline were comparable between responders and non-
responders in the galantamine-treated patients, and we feel 
that regression to the mean was likely to have been very lim-
ited in these patient groups).
  Despite the limitations of our study, the presented data 
are the best currently available and provide useful insights 186    Current Alzheimer Research, 2011, Vol. 8, No. 2  Kavanagh et al. 
into the long-term outcome of galantamine treatment. With 
respect to clinicians, our results suggest that consideration 
should be given to continuing galantamine in patients who 
exhibit stable cognition 2-5 months after reaching mainte-
nance doses of galantamine. Furthermore, these data support 
consideration for discontinuation of galantamine treatment in 
patients who exhibit rapid decline 2-5 months after reaching 
maintenance doses. 
  In conclusion, when patients commence galantamine 
therapy, the potential benefits are unknown. However, iden-
tifying and continuing to treat patients who demonstrate im-
provement, stability, or limited cognitive decline (ADAS-
Cog 11 score change from baseline  4 points) 2-5 months 
after reaching maintenance doses of galantamine may allow 
more patients to experience the benefits of long-term galan-
tamine therapy. 
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